Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Sell World Chess (CHSS) by Steve Moore in ShareProphets
- Avoid Trifast (TRI) by Steve Moore in ShareProphets
- Avoid The Magnum Ice Cream Company (MICC) by Steve Moore in ShareProphets
- Buy Relx plc (REL) by Bank of America
- Buy South32 Limited (DI) (S32) by UBS
- Buy Weir Group (WEIR) by UBS
- Buy Relx plc (REL) by UBS
- Avoid Iomart Group (IOM) by Steve Moore in ShareProphets
- Buy Halma (HLMA) by Goldman Sachs
- Sell Ashmore Group (ASHM) by Deutsche Bank
- Hold Mondi (MNDI) by Deutsche Bank
- Hold Schroders (SDR) by Deutsche Bank
- Buy Relx plc (REL) by Deutsche Bank
- Buy Morgan Sindall Group (MGNS) by Deutsche Bank
- Hold GSK (GSK) by Deutsche Bank
- Overweight Unilever (ULVR) by Barclays
- Buy Morgan Sindall Group (MGNS) by Berenberg
- Outperform Rathbones Group (RAT) by RBC Capital
- Overweight Relx plc (REL) by Barclays
- Outperform Relx plc (REL) by Bernstein
Faron Pharmaceuticals Oy (DI) (FARN) Share Price
Health Care Sector
NOTE: This is based on 3 open tips for Faron Pharmaceuticals Oy (DI) (FARN)
| Latest Bid : 53.00p | Latest Ask : 56.00p |
| High Today : 58.90p | Low Today : 52.00p |
| This Years High : 262.50p | This Years Low : 52.00p |
| Volume : 562,355 | MKT Cap : £56.68M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Faron Pharmaceuticals Oy (DI) (FARN) Overview
We are a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system in order to tackle cancer and inflammation. Since our founding in 2007, our goal has been to develop a diverse and unique pipeline rooted in high quality science and innovation. Faron is focused on mastering immune modulation by harnessing endothelial receptors to control and mediate immune responses.Faron Pharmaceuticals Oy (DI) (FARN) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Under Review | Panmure Gordon | Premium Only | 2020-02-07 09:15:00 07/02/2020 | – |
| Buy | Panmure Gordon | Premium Only | 2017-09-07 08:30:00 07/09/2017 | 0.69% |
| Buy | Panmure Gordon | Premium Only | 2017-02-20 14:40:00 20/02/2017 | -37.67% |
Faron Pharmaceuticals Oy (DI) (FARN) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 53.00p | Latest Ask : 56.00p |
| High Today : 58.90p | Low Today : 52.00p |
| This Years High : 262.50p | This Years Low : 52.00p |
| Volume : 562,355 | MKT Cap : £56.68M |
Faron Pharmaceuticals Oy (DI) Overview
We are a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system in order to tackle cancer and inflammation. Since our founding in 2007, our goal has been to develop a diverse and unique pipeline rooted in high quality science and innovation. Faron is focused on mastering immune modulation by harnessing endothelial receptors to control and mediate immune responses.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Faron Pharmaceuticals Oy (DI) Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Under Review | Panmure Gordon | Premium Only | 2020-02-07 09:15:00 07/02/2020 | – |
| Buy | Panmure Gordon | Premium Only | 2017-09-07 08:30:00 07/09/2017 | 0.69% |
| Buy | Panmure Gordon | Premium Only | 2017-02-20 14:40:00 20/02/2017 | -37.67% |